AEON Biopharma Inc
AEON.WS
AEON.WS was delisted on the 26th of April, 2024.
52 hedge funds and large institutions have $7.07M invested in AEON Biopharma Inc in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
2% more funds holding
Funds holding: 51 → 52 (+1)
0% more capital invested
Capital invested by funds: $7.04M → $7.07M (+$31K)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$98.1K |
| 2 |
Parallax Volatility Advisers
San Francisco,
California
|
+$57.5K |
| 3 |
SCM
Shaolin Capital Management
Miami,
Florida
|
+$33.3K |
| 4 |
RA
Ramius Advisors
New York
|
+$20.1K |
| 5 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$12.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Covalis Capital
London,
United Kingdom
|
-$180K |
| 2 |
ECP
Empyrean Capital Partners
Los Angeles,
California
|
-$147K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$36.4K |
| 4 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
-$36K |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$10.6K |
AEON.WS Hedge Fund Activity: Q2 2022 in Review
52 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in AEON Biopharma Inc (AEON.WS) for Q2 2022, worth a combined $7.07M — up 0.44% from $7.04M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AEON.WS positions and 4 closed out — a net gain of 1 holder — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Cantor Fitzgerald, adding an estimated $98.1K. The largest seller was Covalis Capital, exiting entirely with an estimated $180K sold.
- 52 institutional investors held AEON Biopharma Inc (AEON.WS) as of Q2 2022, up from 51 in Q1 2022.
- Funds reported $7.07M of AEON Biopharma Inc stock for Q2 2022, up 0.44% quarter-over-quarter.
- 5 funds opened new AEON Biopharma Inc positions in Q2 2022 and 4 closed out, a net change of +1 holder.
- The largest AEON Biopharma Inc buyer in Q2 2022 was Cantor Fitzgerald, an estimated $98.1K added.
- The largest AEON Biopharma Inc seller in Q2 2022 was Covalis Capital, an estimated $180K sold.
Based on aggregated 13F filings for Q2 2022.